Tyrosine kinase targets in drug discovery

Drugs of the Future

Volumn 28, Issue 7, 2003, Pages 679-697

  Grosios, Konstantina ^a   Traxler, Peter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; BCR ABL PROTEIN; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; LAPATINIB; MONOCLONAL ANTIBODY; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; SMALL MOLECULE TRANSPORT AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE REARRANGEMENT; MAMMAL CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 0142041989     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.07.857184     Document Type: Review

References (232)

1. Manning, G., Whyte, D.B., Martinez, R., Hunter, T., Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298: 1912-34.
2. Workman, P. Towards genomic cancer pharmacology: Innovative drugs for the new millennium. Curr Opin Oncol Endocr Metab Invest Drugs 2000, 2: 21-5.
3. Traxler, P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 2003, 7: 215-34.
4. Druker, B.J. Imatinib and chronic myeloid leukemia: Validating the promise of molecularly targeted therapy. Eur J Cancer 2002, 38 (Suppl. 5): S70-6.
5. Joensuu, H., Roberts, P.J., Sarlomo-Rikala, M. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344: 1052-6.
6. Rubin, B.P., Schuetze, S.M., Eary, J.F. et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002, 20: 3586-91.
7. Lawrence, D.S., Niu, J. Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol Ther 1998, 77: 81-114.
8. Traxler, P.M., Furet, P., Mett, H., Buchdunger, E., Meyer, T., Lydon, N. 4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 1996, 39: 2285-92.
9. Trumpp-Kallmeyer, S., Rubin, J.R., Humblet, C., Hamby, J.M., Hollis Showalter, H.D. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem 1998, 41: 1752-63.
10. Furet, P., Caravatti, G., Lydon, N. et al. Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput Aided Mol Des 1995, 9: 465-72.
11. Palmer, B.D., Trumpp-Kallmeyer, S., Fry, D.W., Nelson, J.M., Showalter, H.D., Denny, W.A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding. J Med Chem 1997, 40: 1519-29.
12. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103: 211-25.
13. Schlessinger, J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110: 669-72.
14. Hunter, T. The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect 1998-99, 94: 81-119.
15. Hunter, T. Signaling - 2000 and beyond. Cell 2000, 100: 113-27.
16. Rebay, I. Keeping the receptor tyrosine kinase signaling pathway in check: Lessons from Drosophila. Dev Biol 2002, 251: 1-17.
17. Hynes, N.E., Horsch, K., Olayioye, M.A., Badache, A. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 2001, 8: 151-9.
18. Jones, N., Iljin, K., Dumont, D.J., Alitalo, K. Tie receptors: New modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2001, 2: 257-67.
19. Neet, K., Hunter, T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1996, 1: 147-69.
20. Schlessinger, J. How receptor tyrosine kinases activate Ras. Trends Biochem Sci 1993, 18: 273-5.
21. Wittinghofer, A., Nassar, N. How Ras-related proteins talk to their effectors. Trends Biochem Sci 1996, 21: 488-91.
22. Pertseva, M.N., Shpakov, A.O., Plesneva, S.A., Kuznetsova, L.A. A novel view on the mechanisms of action of insulin and other insulin superfamily peptides: Involvement of adenylyl cyclase signaling system. Comp Biochem Physiol B Biochem Mol Biol 2003, 134: 11-36.
23. Veillette, A., Bookman, M.A., Horak, E.M., Bolen, J.B. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell 1988, 55: 301-8.
24. Cloutier, J.F., Veillette, A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999, 189: 111-21.
25. Olayioye, M.A., Beuvink, I., Horsch, K., Daly, J.M., Hynes, N.E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999, 274: 17209-18.
26. Karin, M., Hunter, T. Transcriptional control by protein phosphorylation: Signal transmission from the cell surface to the nucleus. Curr Biol 1995, 5: 747-57.
27. Himanen, J.P., Rajashankar, K.R., Lackmann, M., Cowan, C.A., Henkemeyer, M., Nikolov, D.B. Crystal structure of an Eph receptor-ephrin complex. Nature 2001, 414: 933-8.
28. Jiang, G., Hunter, T. Receptor signaling: When dimerization is not enough. Curr Biol 1999, 9: R568-71.
29. Olayioye, M.A., Graus-Porta, D., Beerli, R.R., Rohrer, J., Gay, B., Hynes, N.E. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 1998, 18: 5042-51.
30. Dikic, I., Giordano, S. Negative receptor signalling. Curr Opin Cell Biol 2003, 15: 128-35.
31. Binns, K.L., Taylor, P.P., Sicheri, F., Pawson, T., Holland, S.J. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol Cell Biol 2000, 20: 4791-805.
32. Schmidt, M.H., Furnari, F.B., Cavenee, W.K., Bogler, O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci USA 2003, 100: 6505-10.
33. Blume-Jensen, P., Hunter, T. Oncogenic kinase signalling. Nature 2001, 411: 355-65.
34. Robertson, S.C., Tynan, J.A., Donoghue, D.J. RTK mutations and human syndromes when good receptors turn bad. Trends Genet 2000, 16: 265-71. Erratum in: Trends Genet 2000, 16: 368.
35. Robertson, S.C., Tynan, J.A., Donoghue, D.J. RTK mutations and human syndromes when good receptors turn bad. Trends Genet 2000, 16: 265-71. Erratum in: Trends Genet 2000, 16: 368.
36. Leonard, W.J. Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001, 1: 200-8.
37. Leonard, W.J. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 2001, 73: 271-7.
38. Cheng, G., Ye, Z.S., Baltimore, D. Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction. Proc Natl Acad Sci USA 1994, 91: 8152-5.
39. Maas, A., Dingjan, G.M., Grosveld, F., Hendriks, R.W. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. J Immunol 1999, 162: 6526-33.
40. Ferguson, S.S. Receptor tyrosine kinase transactivation: Fine-tuning synaptic transmission. Trends Neurosci 2003, 26: 119-22.
41. Chaudhury, A.R., Gerecke, K.M., Wyss, J.M., Morgan, D.G., Gordon, M.N., Carroll, S.L. Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol 2003, 62: 42-54.
42. de Jong, J.S., van Diest, P.J., van der Valk, P., Baak, J.P. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998, 184: 53-7.
43. de Jong, J.S., van Diest, P.J., van der Valk, P., Baak, J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol 1998, 184: 44-52.
44. Zhang, B., Salituro, G., Szalkowski, D. et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 284: 974-7.
45. Barrio, D.A., Williams, P.A., Cortizo, A.M., Etcheverry, S.B. Synthesis of a new vanadyl(IV) complex with trehalose (TreVO): Insulin-mimetic activities in osteoblast-like cells in culture. J Biol Inorg Chem 2003, 8: 459-68.
46. Buchdunger, E., Zimmermann, J., Mett, H. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamino-pyrimidine derivative. Cancer Res 1996, 56: 100-4.
47. Moyer, J.D., Barbacci, E.G., Iwata, K.K. et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57: 4838-48.
48. Wakeling, A.E., Guy, S.P., Woodburn, J.R. et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62: 5749-54.
49. Fong, T.A., Shawver, L.K., Sun, L. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59: 99-106.
50. Nicholson, S., Richard, J., Sainsbury, C. et al. Epidermal growth factor receptor (EGFr): Results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991, 63: 146-50.
51. Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S., Sugimachi, K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990, 50: 7077-80.
52. Ekstrand, A.J., James, C.D., Cavenee, W.K., Seliger, B., Pettersson, R.F., Collins, V.P. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991, 51: 2164-72.
53. Hiesiger, E.M., Hayes, R.L., Pierz, D.M., Budzilovich, G.N. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol 1993, 16: 93-104.
54. Neal, D.E., Sharples, L., Smith, K., Fennelly, J., Hall, R.R., Harris, A.L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990, 65: 1619-25.
55. Iihara, K., Shiozaki, H., Tahara, H. et al. Prognostic significance of transforming growth factor-α in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 1993, 71: 2902-9.
56. Graus-Porta, D., Beerli, R.R., Daly, J.M., Hynes, N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16: 1647-55.
57. Karunagaran, D., Tzahar, E., Beerli, R.R. et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J 1996, 15: 254-64.
58. Slamon, D.J., Godolphin, W., Jones, L.A. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244: 707-12.
59. Karameris, A., Kanavaros, P., Aninos, D. et al. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol Res Pract 1993, 189: 133-7.
60. Salomon, D.S., Brandt, R., Ciardiello, F., Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19: 183-232.
61. Moscatello, D.K., Holgado-Madruga, M., Emlet, D.R., Montgomery, R.B., Wong, A.J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998, 273: 200-6.
62. Tang, C.K., Gong, X.Q., Moscatello, D.K., Wong, A.J., Lippman, M.E. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000, 60: 3081-7.
63. Bruns, C.J., Solorzano, C.C., Harbison, M.T. et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000, 60: 2926-35.
64. Kari, C., Chan, T.O., Rocha de Quadros, M., Rodeck, U. Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res 2003, 63: 1-5.
65. Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, J.F., Arteaga, C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001, 61: 8887-95.
66. Anderson, N.G., Ahmad, T., Chan, K., Dobson, R., Bundred, N.J. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001, 94: 774-82.
67. Ciardiello, F., Caputo, R., Bianco, R. et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001, 7: 1459-65.
68. Hirata, A., Ogawa, S., Kometani, T. et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002, 62: 2554-60.
69. Moasser, M.M., Basso, A., Averbuch, S.D., Rosen, N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001, 61: 7184-8.
70. Anido, J., Matar, P., Albanell, J. et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003, 9: 1274-83.
71. Williams, K.J., Telfer, B.A., Stratford, I.J., Wedge, S.R. ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002, 86: 1157-61.
72. Matsuo, M., Sakurai, H., Saiki, I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2003, 2: 557-61.
73. Ciardiello, F., Caputo, R., Bianco, R. et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6: 2053-63.
74. Baselga, J., Averbuch, S.D. ZD1839 ("Iressa") as an anticancer agent. Drugs 2000, 60: 33-40.
75. Albanell, J., Rojo, F., Averbuch, S. et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002, 20: 110-24.
76. Ranson, M., Hammond, L.A., Ferry, D. et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 2002, 20: 2240-50.
77. Ng, S.S., Tsao, M.S., Nicklee, T., Hedley, D.W. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002, 1: 777-83.
78. Pollack, V.A., Savage, D.M., Baker, D.A. et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999, 291: 739-48.
79. Norman, P. OSI-774 OSI Pharmaceuticals. Curr Opin Investig Drugs 2001, 2: 298-304.
80. Rusnak, D.W., Affleck, K., Cockerill, S.G. et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 2001, 61: 7196-203.
81. Xia, W., Mullin, R.J., Keith, B.R. et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21: 6255-63.
82. Smaill, J.B., Rewcastle, G.W., Loo, J.A. et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)-pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem 2000, 43: 1380-97.
83. Slichenmyer, W.J., Elliott, W.L., Fry, D.W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001, 28: 80-5.
84. Gieseg, M.A., de Bock, C., Ferguson, L.R., Denny, W.A. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001, 12: 683-90.
85. Nelson, J.M., Fry, D.W. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 2001, 276: 14842-7.
86. Erlichman, C., Boerner, S.A., Hallgren, C.G. et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001, 61: 739-48.
87. Allen, L.F., Lenehan, P.F., Eiseman, I.A., Elliott, W.L., Fry, D.W. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002, 29: 11-21.
88. Bridges, A.J. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999, 6: 825-43.
89. Torrance, C.J., Jackson, P.E., Montgomery, E. et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000, 6: 1024-8.
90. 2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8: 289-93.
91. Kerbel, R., Folkman, J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2: 727-39.
92. Ferrara, N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000, 55: 15-35.
93. Gerber, H.P., Ferrara, N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003, 81: 20-31.
94. Vaquero, J., Zurita, M., Morales, C., Cincu, R., Oya, S. Expression of vascular permeability factor in glioblastoma specimens: Correlation with tumor vascular endothelial surface and peritumoral edema. J Neurooncol 2000, 49: 49-55.
95. Gabrilovich, D.I., Chen, H.L., Girgis, K.R. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2: 1096-103.
96. Gilliland, D.G., Griffin, J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100: 1532-42.
97. Liang, D.C., Shih, L.Y., Hung, I.J. et al. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer 2002, 94: 3292-8.
98. Liang, D.C., Shih, L.Y., Hung, I.J. et al. FLT3-TKD mutation in childhood acute myeloid leukemia. Leukemia 2003, 17: 883-6.
99. Nakao, M., Yokota, S., Iwai, T. et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10: 1911-8.
100. Yokota, S., Kiyoi, H., Nakao, M. et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997, 11: 1605-9.
101. Yamamoto, Y., Kiyoi, H., Nakano, Y. et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97: 2434-9.
102. Wood, J.M., Bold, G., Buchdunger, E. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60: 2178-89.
103. Lin, B., Podar, K., Gupta, D. et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002, 62: 5019-26.
104. Drevs, J., Muller-Driver, R., Wittig, C. et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002, 62: 4015-22.
105. Drevs, J., Hofmann, I., Hugenschmidt, H. et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000, 60: 4819-24.
106. Xu, L., Yoneda, J., Herrera, C., Wood, J., Killion, J.J., Fidler, I.J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000, 16: 445-54.
107. Yano, S., Herbst, R.S., Shinohara, H. et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000, 6: 957-65.
108. Mross, K., Fuxius, S., Drevs, J. Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/plasma - what is a useful tool in clinical studies of antiangiogenic drugs? Int J Clin Pharmacol Ther 2002, 40: 573-4.
109. Hennequin, L.F., Thomas, A.P., Johnstone, C. et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 1999, 42: 5369-89.
110. Hennequin, L.F., Stokes, E.S., Thomas, A.P. et al. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002, 45: 1300-12.
111. Carlomagno, F., Vitagliano, D., Guida, T. et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62: 7284-90.
112. Ciardiello, F., Caputo, R., Damiano, V. et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003, 9: 1546-56.
113. Wedge, S.R., Ogilvie, D.J., Dukes, M. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62: 4645-55.
114. Glade-Bender, J., Kandel, J.J., Yamashiro, D.J. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003, 3: 263-76.
115. Laird, A.D., Vajkoczy, P., Shawver, L.K. et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000, 60: 4152-60.
116. Laird, A.D., Christensen, J.G., Li, G. et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002, 16: 681-90.
117. Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9: 327-37.
118. O'Farrell, A.M., Abrams, T.J., Yuen, H.A. et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101: 3597-605.
119. Dickson, C., Spencer-Dene, B., Dillon, C., Fantl, V. Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors. Breast Cancer Res 2000, 2: 191-6.
120. Moroni, E., Dell'Era, P., Rusnati, M., Presta, M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res 2002, 11: 19-32.
121. Cappellen, D., De Oliveira, C., Ricol, D. et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23: 18-20.
122. Chesi, M., Brents, L.A., Ely, S.A. et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001, 97: 729-36.
123. Manetti, F., Botta, M. Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK). Curr Pharm Des 2003, 9: 567-81.
124. George, D. Platelet-derived growth factor receptors: A therapeutic target in solid tumors. Semin Oncol 2001, 28: 27-33.
125. Ostman, A., Heldin, C.H. Involvement of platelet-derived growth factor in disease: Development of specific antagonists. Adv Cancer Res 2001, 80: 1-38.
126. Hines, S.J., Litz, J.S., Krystal, G.W. Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors. Breast Cancer Res Treat 1999, 58: 1-10.
127. Krystal, G.W., Hines, S.J., Organ, C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996, 56: 370-6.
128. Heinrich, M.C., Blanke, C.D., Druker, B.J., Corless, C.L. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002, 20: 1692-703.
129. Fabbro, D., Ruetz, S., Bodis, S. et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000, 15: 17-28.
130. Cools, J., Stover, E.H., Boulton, C.L. et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003, 3: 459-69.
131. Levis, M., Allebach, J., Tse, K.F. et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002, 99: 3885-91.
132. Weeraratna, A.T., Dalrymple, S.L., Lamb, J.C. et al. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 2001, 7: 2237-45.
133. Miknyoczki, S.J., Chang, H., Klein-Szanto, A., Dionne, C.A., Ruggeri, B.A. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 1999, 5: 2205-12.
134. Laird, A.D., Cherrington, J.M. Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin Investig Drugs 2003, 12: 51-64.
135. Kelly, L.M., Yu, J.C., Boulton, C.L. et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002, 1: 421-32.
136. Vigneri, P., Wang, J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001, 7: 228-34.
137. Plattner, R., Kadlec, L., DeMali, K.A., Kazlauskas, A., Pendergast, A.M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999, 13: 2400-11.
138. Nowell, P.C., Hungerford, D.A. The etiology of leukemia: Some comments on current studies. Semin Hematol 1966, 3: 114-21.
139. Deininger, M.W., Goldman, J.M., Melo, J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96: 3343-56.
140. Buchdunger, E., O'Reilly, T., Wood, J. Pharmacology of imatinib (STI571). Eur J Cancer 2002, 38: S28-36.
141. Carroll, M., Ohno-Jones, S., Tamura, S. et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90: 4947-52.
142. Buchdunger, E., Cioffi, C.L., Law, N. et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295: 139-45.
143. Heinrich, M.C., Griffith, D.J., Druker, B.J., Wait, C.L., Ott, K.A., Zigler, A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96: 925-32.
144. Druker, B.J., Tamura, S., Buchdunger, E. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2: 561-6.
145. Horita, M., Andreu, E.J., Benito, A. et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000, 191: 977-84.
146. Beran, M., Cao, X., Estrov, Z. et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998, 4: 1661-72.
147. Gambacorti-Passerini, C., le Coutre, P., Mologni, L. et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997, 23: 380-94.
148. Dan, S., Naito, M., Tsuruo, T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ 1998, 5: 710-5.
149. Kantarjian, H.M., O'Brien, S., Cortes, J.E. et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002, 100: 1590-5.
150. Kantarjian, H.M., Cortes, J., O'Brien, S. et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002, 99: 3547-53.
151. Talpaz, M., Silver, R.T., Druker, B.J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002, 99: 1928-37.
152. Sawyers, C.L., Hochhaus, A., Feldman, E. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002, 99: 3530-9.
153. Joensuu, H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Klin 2002, 97 (Suppl. 1): 28-30.
154. Morel, F., Bris, M.J., Herry, A. at al. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol 2003, 70: 235-9.
155. Azam, M., Latek, R.R., Daley, G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112: 831-43.
156. Mahon, F.X., Belloc, F., Lagarde, V. et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101: 2368-73.
157. + leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000, 92: 1641-50.
158. + chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002, 28: 75-85.
159. Ricci, C., Scappini, B., Divoky, V. at el. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 2002, 62: 5995-8.
160. Campbell, L.J., Patsouris, C., Rayeroux, K.C., Somana, K., Januszewicz, E.H., Szer, J. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 2002, 139: 30-3.
161. Gorre, M.E., Mohammed, M., Ellwood, K. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293: 876-80.
162. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289: 1938-42.
163. Gorre, M.E., Ellwood-Yen, K., Chiosis, G., Rosen, N., Sawyers, C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002, 100: 3041-4.
164. Ross, J.S., Gray, K., Gray, G.S., Worland, P.J., Rolfe, M. Anticancer antibodies. Am J Clin Pathol 2003, 119: 472-85.
165. Cragg, M.S., French, R.R., Glennie, M.J. Signaling antibodies in cancer therapy. Curr Opin Immunol 1999, 11: 541-7.
166. Goldenberg, M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999, 21: 309-18.
167. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344: 783-92.
168. Vogel, C., Cobleigh, M.A., Tripathy, D. et al. First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer. A preliminary report. Eur J Cancer 2001, 37: 25-9.
169. Tan-Chiu, E., Piccart, M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002, 1: 57-63.
170. Gilhma, I. Theranostics, an emerging tool in drug discovery and
171. Konecny, G., Slamon, D.J. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt) 2002, 16: 1576-8.
172. Dowsett, M., Bartlett, J., Ellis, I.O. et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003, 199: 418-23.
173. Bruns, C.J., Harbison, M.T., Davis, D.W. et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000, 6: 1936-48.
174. Inoue, K., Slaton, J.W., Perrotte, P. et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000, 6: 4874-84.
175. Overholser, J.P., Prewett, M.C., Hooper, A.T., Waksal, H.W., Hicklin, D.J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000, 89: 74-82.
176. Maung, K., Lee, D., DeGrendele, H.C. et al. Highlights from 27th congress of the European Society for Medical Oncology. Nice, France, October 18-22, 2002. Clin Colorectal Cancer 2002, 2: 140-5.
177. Needle, M.N. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002, 29: 55-60.
178. Kies, M.S., Harari, P.M. Cetuximab (Imclone/Merck/Bristol-Myers Squibb). Curr Opin Investig Drugs 2002, 3: 1092-100.
179. Duvic, M., Cather, J., Maize, J., Frankel, A.E. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol 1998, 58: 87-90.
180. Frankel, A.E., McCubrey, J.A., Miller, M.S. et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000, 14: 576-85.
181. Frankel, A.E., Powell, B.L., Lilly, M.B. Diphtheria toxin conjugate therapy of cancer. Cancer Chemother Biol Response Modif 2002, 20: 301-13.
182. Wraight, C.J., White, P.J. Antisense oligonucleotides in cutaneous therapy. Pharmacol Ther 2001, 90: 89-104.
183. Andrews, D.W., Resnicoff, M., Flanders, A.E. et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001, 19: 2189-200.
184. Li, M., Ye, C., Feng, C. et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002, 8: 3570-8.
185. Kagiyama, S., Qian, K., Kagiyama, T., Phillips, M.I. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 2003, 41: 824-9.
186. Reifenberger, G., Ichimura, K., Reifenberger, J., Elkahloun, A.G., Meltzer, P.S., Collins, V.P. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res 1996, 56: 5141-5.
187. Gaffey, M.J., Frierson, H.F. Jr., Williams, M.E. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: Clinicopathologic correlations. Mod Pathol 1993, 6: 654-9.
188. Reiter, R.E., Sato, I., Thomas, G. et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000, 27: 95-103.
189. Haddad, R., Lipson, K.E., Webb, C.P. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res 2001, 21: 4243-52.
190. Danilkovitch-Miagkova, A., Zbar, B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002, 109: 863-7.
191. Santoro, M., Grieco, M., Melillo, R.M., Fusco, A., Vecchio, G. Molecular defects in thyroid carcinomas: Role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 1995, 133: 513-22.
192. van Weering, D.H., Bos, J.L. Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res 1998, 154: 271-81.
193. Schmidt, L., Duh, F.M., Chen, F. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 1997, 16: 68-73.
194. Irby, R.B., Mao, W., Coppola, D. et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999, 21: 187-90.
195. Biscardi, J.S., Tice, D.A., Parsons, S.J. c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 1999, 76: 61-119.
196. Biscardi, J.S., Maa, M.C., Tice, D.A., Cox, M.E., Leu, T.H., Parsons, S.J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999, 274: 8335-43.
197. Belsches-Jablonski, A.P., Biscardi, J.S., Peavy, D.R., Tice, D.A., Romney, D.A., Parsons, S.J. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001, 20: 1465-75.
198. Blake, R.A., Broome, M.A., Liu, X. et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000, 20: 9018-27.
199. Missbach, M., Jeschke, M., Feyen, J. et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999, 24: 437-49.
200. Shakespeare, W., Yang, M., Bohacek, R. et al. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci USA 2000, 97: 9373-8.
201. Violette, S.M., Guan, W., Bartlett, C. et al. Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone 2001, 28: 54-64.
202. Kaleko, M., Rutter, W.J., Miller, A.D. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990, 10: 464-73.
203. Derynck, R., Goeddel, D.V., Ullrich, A. et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 1987, 47: 707-12.
204. Hirano, H., Lopes, M.B., Laws, E.R. Jr. et al. Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neurooncol 1999, 1: 109-19.
205. All-Ericsson, C., Girnita, L., Seregard, S., Bartolazzi, A., Jager, M.J., Larsson, O. Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002, 43: 1-8.
206. Steller, M.A., Delgado, C.H., Bartels, C.J., Woodworth, C.D., Zou, Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996, 56: 1761-5.
207. Adams, G.R. Autocrine/paracrine IGF-I and skeletal muscle adaptation. J Appl Physiol 2002, 93: 1159-67.
208. Kanter-Lewensohn, L., Girnita, L., Girnita, A. et al. Tamoxifen-induced cell death in malignant melanoma cells: Possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol Cell Endocrinol 2000, 165: 131-7.
209. Toretsky, J.A., Kalebic, T., Blakesley, V., LeRoith, D., Helman, L.J. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997, 272: 30822-7.
210. Khandwala, H.M., McCutcheon, I.E., Flyvbjerg, A., Friend, K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000, 21: 215-44.
211. Takahama, M., Tsutsumi, M., Tsujiuchi, T. et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 1999, 5: 2506-10.
212. Suri, C., Jones, P.F., Patan, S. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87: 1171-80.
213. Maisonpierre, P.C., Suri, C., Jones, P.F. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277: 55-60.
214. Valenzuela, D.M., Griffiths, J.A., Rojas, J. et al. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999, 96: 1904-9.
215. Lin, P., Polverini, P., Dewhirst, M., Shan, S., Rao, P.S., Peters, K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997, 100: 2072-8.
216. Stahl, P., Kissau, L., Mazitschek, R., Giannis, A., Waldmann, H. Natural product derived receptor tyrosine kinase inhibitors: Identification of IGF1R, Tie-2, and VEGFR-3 inhibitors. Angew Chem Int Ed Engl 2002, 41: 1174-8.
217. Cheng, N., Brantley, D.M., Chen, J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002, 13: 75-85.
218. Easty, D.J., Hill, S.P., Hsu, M.Y. et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999, 84: 494-501.
219. Orsulic, S., Kemler, R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 2000, 113: 1793-802.
220. Walker-Daniels, J., Hess, A.R., Hendrix, M.J., Kinch, M.S. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 2003, 162: 1037-42.
221. Walker-Daniels, J., Coffman, K., Azimi, M. et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999, 41: 275-80.
222. Ogawa, K., Pasqualini, R., Lindberg, R.A., Kain, R., Freeman, A.L., Pasquale, E.B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000, 19: 6043-52.
223. Zelinski, D.P., Zantek, N.D., Stewart, J.C., Irizarry, A.R., Kinch, M.S. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001, 61: 2301-6.
224. Brantley, D.M., Cheng, N., Thompson, E.J. et al. Soluble EphA receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002, 21: 7011-26.
225. Sikora, K., Advani, S., Koroltchouk, V. et al. Essential drugs for cancer therapy: A World Health Organization consultation. Ann Oncol 1999, 10: 385-90.
226. Perou, C.M., Jeffrey, S.S., van de Rijn, M. et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999, 96: 9212-7.
227. Perou, C.M., Sorlie, T., Eisen, M.B. et al. Molecular portraits of human breast tumours. Nature 2000, 406: 747-52.
228. Kudoh, K., Ramanna, M., Ravatn, R. et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000, 60: 4161-6.
229. Bardelli, A., Parsons, D.W., Silliman, N. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003, 300: 949.
230. Dancey, J., Sausville, E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003, 2: 296-313.
231. Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100: 1014-8.
232. Luzzatto, L., Melo, J.V. Acquired resistance to imatinib mesylate: Selection for pre-existing mutant cells. Blood 2002, 100: 1105.